In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO and C-suite leaders from the CDMO ecosystem, exploring the overlooked trends for 2026.

Nick Fortin, CEO, Codis
Ankit Gupta, CEO, InstaPill
Eric Edwards, MD, PhD, CEO, Phlow USA
Dirk T. Lange, CEO, Pyramid Pharma Services
Kaan-Fabian Kekec, Partner, Simon-Kucher Healthcare and Life Sciences
J.D. Mowery, President, CDMO Division, Bora Pharmaceuticals
Matthew Bio, CSO, Cambrex and President, Snapdragon Chemistry
Bill Vincent, Biotech Entrepreneur, CEO and Board Member
Philip Macnabb, CEO, Curia
Christiane Bardroff, COO Leader
Jason Anderson, CEO, Ensera
Mark B, Anonymous CEO (not to be quoted by name)
Adam Siebert, Managing Director, L.E.K. Consulting
Stephen Dilly, CEO, Sonoma Biotherapeutics
Elisabeth Stampa, CEO, Medichem
Jon Alberdi, CEO, Vivebiotech
Derek Hennecke, Founder, Investor and Board Member
Bruce Thompson, CTO, Kincell Bio

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

M2M Pulse: 7 Trends CDMO You Can’t Ignore